Burkitt lymphoma in adolescents and young adults: management challenges

References

• BurkittDA sarcoma involving the jaws in African childrenBr J Surg19584619721822313628987
   PubMed Web of Science ®Google Scholar
• BurkittDO’ConorGTMalignant lymphoma in African children. I. A clinical syndromeCancer19611425826914448554
   PubMed Web of Science ®Google Scholar
• MagrathIJaffeESBhatiaKBurkitt’s lymphomaKnowlesDMNeoplastic HematopathologyPhiladelphia, PALippincott Williams & Wilkins2001953986
   Google Scholar
• MagrathITBurkitt’s lymphoma. The small noncleaved cell lymphomasCanellosGPListerTASklarJLThe LymphomasPhiladelphia, PAWB Saunders1998413422
   Google Scholar
• LeonciniLRaphaelMSteinHHarrisNJaffeEKluinPBurkitt lymphomaSwerdlowSCampoEHarrisNWHO Classification of Tumours of Haematopoietic and Lymphoid TissuesLyonIARC Press2008
   Google Scholar
• CostaLJXavierACWahlquistAEHillEGTrends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 casesBlood2013121244861486623641015
   PubMed Web of Science ®Google Scholar
• MagrathIEpidemiology: clues to the pathogenesis of Burkitt lymphomaBr J Haematol2012156674475622260300
   PubMed Web of Science ®Google Scholar
• OgwangMDBhatiaKBiqqarRJMbulaiteyeSMIncidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisitedInt J Cancer2008123112658266318767045
   PubMed Web of Science ®Google Scholar
• MortonLMWangSSDevesaSSHartgePWeisenburgerDDLinetMSLymphoma incidence patterns by WHO subtype in the United States, 1992–2001Blood2006107126527616150940
   PubMed Web of Science ®Google Scholar
• SantMAllemaniCTereanuCHAEMACARE Working GroupIncidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE projectBlood2010116193724373420664057
   PubMed Web of Science ®Google Scholar
• MbulaiteyeSMAndersonWFFerlayJPediatric, elderly, and emerging adult-onset peaks in Burkitt’s lymphoma incidence diagnosed in four continents, excluding AfricaAm J Hematol201287657357822488262
   PubMed Web of Science ®Google Scholar
• SwerdlowSHCampoEHarrisNLWHO Classification of Tumours of Haematopoietic and Lymphoid TissuesLyonIARC Press2008
   Google Scholar
• ArmitageJOWeisenburgerDDNew approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification ProjectJ Clin Oncol1998168278027959704731
   PubMed Web of Science ®Google Scholar
• LauriniJAPerryAMBoilesenEClassification of non-Hodgkin lymphoma in Central and South America: a review of 1028 casesBlood2012120244795480123086753
   PubMed Web of Science ®Google Scholar
• BoermaEGvan ImhoffGWAppelIMVeegerNJKluinPMKluin-NelemansJCGender and age-related differences in Burkitt lymphoma–epidemiological and clinical data from the NetherlandsEur J Cancer200440182781278715571961
   PubMed Web of Science ®Google Scholar
• SmithAHowellDPatmoreRJackARomanEIncidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research NetworkBr J Cancer2011105111684169222045184
   PubMed Web of Science ®Google Scholar
• ShielsMSPfeifferRMHallHIProportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007JAMA2011305141450145921486978
   PubMed Web of Science ®Google Scholar
• Guech-OngeyMSimardEPAndersonWFAIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?Blood2010116255600560420813897
   PubMed Web of Science ®Google Scholar
• MbulaiteyeSMMortonLMSampsonJNMedical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the interlymph non-Hodgkin Lymphoma Subtypes ProjectJ Natl Cancer Inst Monogr201420144810611425174031
   PubMedGoogle Scholar
• BurkeMEAlbrittonKMarinaNChallenges in the recruitment of adolescents and young adults to cancer clinical trialsCancer2007110112385239317918260
   PubMed Web of Science ®Google Scholar
• CastilloJJWinerESOlszewskiAJPopulation-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results databaseCancer2013119203672367923913575
   PubMed Web of Science ®Google Scholar
• BellanCLazziSHummelMImmunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomasBlood200510631031103615840698
   PubMed Web of Science ®Google Scholar
• HechtJLAsterJCMolecular biology of Burkitt’s lymphomaJ Clin Oncol200018213707372111054444
   PubMed Web of Science ®Google Scholar
• KlapprothKWirthTAdvances in the understanding of MYC-induced lymphomagenesisBr J Haematol2010149448449720346013
   PubMed Web of Science ®Google Scholar
• MüllerJRJanzSGoedertJJPotterMRabkinCSPersistence of immunoglobulin heavy chain/c-myc recombination-positive lymphocyte clones in the blood of human immunodeficiency virus-infected homosexual menProc Natl Acad Sci U S A19959214657765817604036
   PubMed Web of Science ®Google Scholar
• Dalla-FaveraRBregniMEriksonJPattersonDGalloRCCroceCMHuman c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cellsProc Natl Acad Sci U S A19827924782478276961453
   PubMed Web of Science ®Google Scholar
• ar-RushdiANishikuraKEriksonJWattRRoveraGCroceCMDifferential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphomaScience198322246223903936414084
   PubMed Web of Science ®Google Scholar
• PelicciPGKnowlesDM2ndMagrathIDalla-FaveraRChromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphomaProc Natl Acad Sci U S A1986839298429883458257
   PubMed Web of Science ®Google Scholar
• NeriABarrigaFKnowlesDMMagrathITDalla-FaveraRDifferent regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphomaProc Natl Acad Sci U S A1988858274827522833750
   PubMed Web of Science ®Google Scholar
• RamiroARJankovicMCallenERole of genomic instability and p53 in AID-induced c-MYC-Igh translocationsNature2006440708010510916400328
   PubMed Web of Science ®Google Scholar
• RobbianiDFDeroubaixSFeldhahnNPlasmodium infection promotes genomic instability and AID-dependent B cell lymphomaCell2015162472773726276629
   PubMed Web of Science ®Google Scholar
• MosialosGBirkenbachMYalamanchiliRVanArsdaleTWareCKieffEThe Epstein-Barr virus transforming protein LMP-1 engages signaling proteins for the tumor necrosis factor receptor familyCell19958033893997859281
   PubMed Web of Science ®Google Scholar
• CheneADonatiDOremJEndemic Burkitt’s lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virusSemin Cancer Biol200919641142019897039
   PubMed Web of Science ®Google Scholar
• ParkinDMSitasFChirenjeMSteinLAbrattRWabingaHPart I: Cancer in Indigenous Africans–burden, distribution, and trendsLancet Oncol20089768369218598933
   PubMed Web of Science ®Google Scholar
• MorrowRHJrEpidemiological evidence for the role of falciparum malaria in the pathogenesis of Burkitt’s lymphomaIARC Sci Publ198560177186
   Google Scholar
• AkaPVilaMCJariwalaAEndemic Burkitt lymphoma is associated with strength and diversity of Plasmodium falciparum malaria stage-specific antigen antibody responseBlood2013122562963523645841
   PubMed Web of Science ®Google Scholar
• HavelangeVPepermansXAmeyeGGenetic differences between paediatric and adult Burkitt lymphomasBr J Hematol20161731137144
   PubMed Web of Science ®Google Scholar
• DaveSSFuKWrightGWMolecular diagnosis of Burkitt’s lymphomaN Engl J Med2006354232431244216760443
   PubMed Web of Science ®Google Scholar
• SwerdlowSHCampoEPileriSAThe 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood2016127202375239026980727
   PubMed Web of Science ®Google Scholar
• HasserjianRPOttGElenitoba-JohnsonKSBalague-PonzOde JongDde LevalLCommentary on the WHO classification of tumors of lymphoid tissues (2008): “gray zone” lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphomaJ Hematop200922899519669187
   PubMedGoogle Scholar
• GascoyneRDMagrathITSehnLBurkitt lymphomaArmitageJOMauchPMHarrisNLCoiffierBDalla-FaveraRNon-Hodgkin Lymphomas2nd edPhiladelphia, PAWolters Kluwer and Lippincott Williams & Wilkins2010334357
   Google Scholar
• BlumKALozanskiGByrdJCAdult Burkitt leukemia and lymphomaBlood2004104103009302015265787
   PubMed Web of Science ®Google Scholar
• WilsonWHBrombergJEStetler-StevensonMDetection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphomaHaematologica20149971228123524727817
   PubMed Web of Science ®Google Scholar
• JacobsonCLaCasceAHow I treat Burkitt Lymphoma in adultsBlood2014124192913292025258344
   PubMed Web of Science ®Google Scholar
• MurphySBClassification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adultsSemin Oncol1980733323397414342
   PubMed Web of Science ®Google Scholar
• WaxmanIMHochbergJCairoMSNon-Hodgkin LymphomaKliegmanRMBehrmanREJensonHBStantonBFNelson Textbook of Pediatrics19th edNew York, NYElsevier Inc201117391745
   Google Scholar
• van DongenJJvan der VeldenVHBrüggemannMOrfaoAMinimal residual disease diagnostic in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesBlood2015125263996400925999452
   PubMed Web of Science ®Google Scholar
• BassanRSpinelliOMinimal residual disease monitoring in adult ALL to determine therapyCurr Hematol Malig Rep2015102869525929769
   PubMed Web of Science ®Google Scholar
• BassanRMainoECortelazzoSLymphoblastic lymphoma: an update review on biology, diagnosis, and treatmentEur J Haematol201696544746026679753
   PubMed Web of Science ®Google Scholar
• Coustan-SmithESandlundJTPerkinsSLMinimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children’s oncology groupJ Clin Oncol2009272135333539
   PubMed Web of Science ®Google Scholar
• BuschKBorkhardtAWössmannWReiterAHarbottJCombined polymerase chain reaction methods to detect c-myc/IgH rearrangement in childhood Burkitt’s lymphoma for minimal residual disease analysisHaematologica200489781882515257933
   PubMed Web of Science ®Google Scholar
• LovisaFMussolinLCorralLIGH and IGK gene rearrangements as PCR targets for pediatric Burkitt’s lymphoma and mature B-ALL MRD analysisLab Invest200989101182118619668242
   PubMed Web of Science ®Google Scholar
• MussolinLPillonMd’AmoreESMinimal disseminated disease in high-risk Burkitt’s lymphoma identifies patients with different prognosisJ Clin Oncol201129131779178421422413
   PubMed Web of Science ®Google Scholar
• PillonMMussolinLCarraroEDetection of prognostic factors in children and adolescents with Burkitt and diffuse large B-cell lymphoma treated with the AIEOP LNH-97 protocolBr J Haematol Epub201678
   Web of Science ®Google Scholar
• AgsaldaMKusaoITroelstrupDShiramizuBScreening for residual disease in pediatric Burkitt lymphoma using consensus primer poolsAdv Hematol2009200941216319890467
   PubMedGoogle Scholar
• ShiramizuBGoldmanSKusaoIMinimal disease assessment in the treatment of children and adolescent with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children’s oncology group reportBr J Haematol2011153675876321496005
   PubMed Web of Science ®Google Scholar
• ChesonBDHorningSJCoiffierBReport of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working GroupJ Clin Oncol1999174124410561185
   PubMed Web of Science ®Google Scholar
• ChesonBDPfistnerBJuweidMERevised response criteria for malignant lymphomaJ Clin Oncol200725557958617242396
   PubMed Web of Science ®Google Scholar
• ReiterASchrappeMLudwigWDIntensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group reportBlood200095241642110627444
   PubMed Web of Science ®Google Scholar
• JuweidMEStroobantsSHoekstraOSUse of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaJ Clin Oncol200725557157817242397
   PubMed Web of Science ®Google Scholar
• DunleavyKMikhaeelGSehnLHHicksRJWilsonWHThe value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphomaLeuk Lymphoma201051Suppl 1283320658958
   PubMed Web of Science ®Google Scholar
• RiadROmarWSidhomIFalse-positive F-18 uptake in PET/CT studies in pediatric patients with abdominal Burkitt’s lymphomaNucl Med Commun201031323223820032800
   PubMed Web of Science ®Google Scholar
• HutchingsMMikhaeelNGFieldsPANunanTTimothyARPrognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphomaAnn Oncol20051671160116815939713
   PubMed Web of Science ®Google Scholar
• GallaminiAHutchingsMRigacciLEarly interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish studyJ Clin Oncol20072543746375217646666
   PubMed Web of Science ®Google Scholar
• BarringtonSFQianWSomerEJConcordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphomaEur J Nucl Med Mol Imaging201037101824183320505930
   PubMed Web of Science ®Google Scholar
• MeignanMGallaminiAMeignanMGallaminiAHaiounCReport on First International Workshop on Interim-PET-Scan in LymphomaLeuk Lymphoma20095081257126019544140
   PubMed Web of Science ®Google Scholar
• Le RouxPYGastinneTLe GouillSPrognostic value of interim FDG PET/CT in Hodgkin’s lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteriaEur J Nucl Med Mol Imaging20113861064107121308370
   PubMed Web of Science ®Google Scholar
• Minard-ColinVBrugièresLReiterANon-Hodgkin lymphoma in children and adolescent: progress through effective collaboration, current knowledge, and challenge aheadJ Clin Oncol201533272963297426304908
   PubMed Web of Science ®Google Scholar
• SandlundJTBurkitt lymphoma: staging and evaluationBr J Haematol2012156676176522296338
   PubMed Web of Science ®Google Scholar
• FenauxPLaiJLMiauxOZandeckiMJouetJPBautersFBurkitt cell acute leukaemia (L3 ALL) in adults: a report of 18 casesBr J Haematol19897133713762930722
   PubMed Web of Science ®Google Scholar
• PeesHWRadtkeHSchwambornJGrafNThe BMF-protocol for HIV-negative Burkitt’s lymphomas and L3 ALL in adult patients: a high chance for cureAnn Hematol19926552012051457577
   PubMed Web of Science ®Google Scholar
• SoussainCPatteCOstronoffMSmall noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocolsBlood19958536646747833470
   PubMed Web of Science ®Google Scholar
• HoelzerDLudwigWDThielEImproved outcome in adult B-cell acute lymphoblastic leukemiaBlood19968724955088555471
   PubMed Web of Science ®Google Scholar
• MagrathIAddeMShadAAdults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimenJ Clin Oncol19961439259348622041
   PubMed Web of Science ®Google Scholar
• ThomasDACortesJO’brienSHyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemiaJ Clin Oncol19991782461247010561310
   PubMed Web of Science ®Google Scholar
• RizzieriDAJohnsonJLNiedzwieckiDIntensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251Cancer200410071438144815042678
   PubMed Web of Science ®Google Scholar
• LacasceAHowardOLibSModified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicityLeuk Lymphoma200445476176715160953
   PubMed Web of Science ®Google Scholar
• SmelandSBlystadAKKvaloySOTreatment of Burkitt’s/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimensAnn Oncol20041571072107815205201
   PubMed Web of Science ®Google Scholar
• Di NicolaMCarlo-StellaCMariottiJHigh response rate and manageable toxicity with an intensive, short term chemotherapy programme for Burkitt’s lymphoma in adultsBr J Haematol2004126681582015352985
   PubMed Web of Science ®Google Scholar
• TauroSCochraneLLauritzsenGFDose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma) in young adults (<50 years): a comparison of two adapted BFM protocolsAm J Hematol201085426126320201088
   PubMed Web of Science ®Google Scholar
• CairoMSSpostoRPerkinsSLBurkitt’s and Burkitt-lyke lymphoma in children and adolescents: a review of the Children’s Cancer Group experienceBr J Haematol2003120466067012588354
   PubMed Web of Science ®Google Scholar
• MurphySBBowmanWPAbromowitchMResults of treatment of advanced-stage Burkitt’s lymphoma and B cell (Sig+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabineJ Clin Oncol1986412173217393491184
   PubMed Web of Science ®Google Scholar
• HoelzerDWalewskiJDöhnerHImproved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trialBlood2014124263870387925359988
   PubMed Web of Science ®Google Scholar
• ThomasDAFaderlSO’BrienSChemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemiaCancer200610671569158016502413
   PubMed Web of Science ®Google Scholar
• KujawskiLALongoWLWilliamsECA 5-drug regimen maxi-mizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomasCancer Invest2007252879317453819
   PubMed Web of Science ®Google Scholar
• MeadGMBarransSLQianWA prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)Blood200811262248226018612102
   PubMed Web of Science ®Google Scholar
• ChoiMKJunHJLeeSYTreatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in KoreaAnn Hematol200988111099110619288103
   PubMed Web of Science ®Google Scholar
• BarnesJALacasceASFengYEvaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysisAnn Oncol20112281859186421339382
   PubMed Web of Science ®Google Scholar
• CorazzelliGFrigeriFRussoFRDCODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphomaBr J Haematol2012156223424422098541
   PubMed Web of Science ®Google Scholar
• KasamonYLBrodskyRABorowitzMJBrief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemiaLeuk Lymphoma201354348349022835045
   PubMed Web of Science ®Google Scholar
• RiberaJMGarcíaOGrandeCDose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of phase 2 study (Burkimab)Cancer201311991660166823361927
   PubMed Web of Science ®Google Scholar
• DunleavyKPittalugaSShovlinMLow-intensity therapy in adults with Burkitt’s lymphomaN Engl J Med2013369201915192524224624
   PubMed Web of Science ®Google Scholar
• IntermesoliTRambaldiRRossiGHigh cure rates in Burkitt lymphoma and leukemia: Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy programHaematologica201398111718172523753030
   PubMed Web of Science ®Google Scholar
• JainPKantarjianHMCortesJELong term follow-up of de novo or minimally treated Burkitt lymphoma/leukemia (BL/B-ALL) after frontline therapy per the hyper-CVAD regimen with or without rituximab: 20-year cumulative experienceBlood20131223917
   Google Scholar
• RizzieriDAJohnsonJLByrdJCImproved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002Br J Haematol2014165110211124428673
   PubMed Web of Science ®Google Scholar
• HongJKimSJAhnJSTreatment outcomes of rituximab plus hyper-CVAD in Korean patients with sporadic Burkitt or Burkitt-like lymphoma: results of a multicenter analysisCancer Res Treat201547217318125544581
   PubMed Web of Science ®Google Scholar
• MeinhardtABurkhardtBZimmermannMBerlin-Frankfurt-Münster GroupPhase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemiaJ Clin Oncol201028193115312120516455
   PubMed Web of Science ®Google Scholar
• RibragVKoscielnySBosqJRituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trialLancet2016387100362402241127080498
   PubMed Web of Science ®Google Scholar
• MeadGMSydesMRWalewskiJAn international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 studyAnn Oncol20021381264127412181251
   PubMed Web of Science ®Google Scholar
• DivinéMCasassusPKoscielnySBurkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocolAnn Oncol200516121928193516284057
   PubMed Web of Science ®Google Scholar
• TodeschiniGBonifacioMTecchioCIntensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemiaAm J Hematol2012871222522086870
   PubMed Web of Science ®Google Scholar
• WilsonFPBernsJSTumor lysis syndrome: new challenges and recent advancesAdv Chronic Kidney Dis2014211182624359983
   PubMed Web of Science ®Google Scholar
• McBrideAWesterveltPRecognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignanciesJ Hematol Oncol201257523237230
   PubMed Web of Science ®Google Scholar
• van ImhoffGWvan der HoltBMacKenzieMAShort intensive sequential therapy followed autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphomaLeukemia200519694595215800666
   PubMed Web of Science ®Google Scholar
• SweetenhamJWPearceRTaghipourGBlaiseDGisselbrechtCGoldstoneAHAdult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma – outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow TransplantationJ Clin Oncol1996149246524728823324
   PubMed Web of Science ®Google Scholar
• HoffmannCWolfEWyenCAIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effectiveLeuk Lymphoma20064791872188017065000
   PubMed Web of Science ®Google Scholar
• XicoyBRiberaJMMüllerMPETHEMA Group and German HIV Lymphoma CohortDose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patientsLeuk Lymphoma201455102341234824397614
   PubMed Web of Science ®Google Scholar
• OriolARiberaJMEsteveJPETHEMA Group; Spanish Society of HematologyLack of influence of human immunodeficiency virus infection status in the response to therapy and serviva of adult patients with mature B-cell lymphoma or leukemia. Result of the PETHEMA-LAL3/97 studyHaematologica200388444545312681972
   PubMed Web of Science ®Google Scholar
• OriolARiberaJMBrunetSdel PotroEAbellaEEsteveJHighly active antiretroviral therapy and outcome of AIDS-related Burkitt’s lymphoma or leukemia. Results of the PETHEMA-LAL3/97 studyHaematologica200590799099215996943
   PubMed Web of Science ®Google Scholar
• BaikSMbaziiraMWilliamsMA case-control study of Burkitt lymphoma in East Africa: are local health facilities an appropriate source of representative controls?Infect Agents Cancer201271522413839
   PubMed Web of Science ®Google Scholar
• AkaPKawiraEMasaluNIncidence and trends in Burkitt lymphoma in northern Tanzxania from 2000 to 2009Pediatr Blood Cancer20125971234123822618958
   PubMed Web of Science ®Google Scholar
• NgomaTAddeMDurosinmiMTreatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent diseaseBr J Haematol2012158674976222844968
   PubMed Web of Science ®Google Scholar
• BuckleGCCollinsJPSumbaPOFactors influencing time to diagnosis and initiation of treatment of endemic Burkitt Lymphoma among children in Uganda and western Kenya: a cross-sectional surveyInfect Agent Cancer2013813624079452
   PubMed Web of Science ®Google Scholar
• StanleyCCWestmorelandKDHeimlichBJOutcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in MalawiBr J Haematol2016173570571226914979
   PubMed Web of Science ®Google Scholar
• KimHParkESLeeSHClinical outcome of relapsed or refractory Burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescentsCancer Res Treat201446435836525043820
   PubMed Web of Science ®Google Scholar
• PeniketAJRuiz de ElviraMCTaghipourGEuropean Bone Marrow Transplantation (EBMT) Lymphoma RegistryAn EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantationBone Marrow Transplant200331866767812692607
   PubMed Web of Science ®Google Scholar
• AwasthiAAyelloJVan de VenCObinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALLBr J Haematol2015171576377526471982
   PubMed Web of Science ®Google Scholar
• KantarjianHMDeAngeloDJStelljesMInotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemiaN Engl J Med201637574075327292104
   PubMed Web of Science ®Google Scholar
• ToppMSGökbugetNSteinASSafety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia: a multicentre, single-arm, phase 2 studyLancet Oncol2015161576625524800
   PubMed Web of Science ®Google Scholar
• GökbugetNDombretHBonifacioMLong-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL)Blood2015126680
   Web of Science ®Google Scholar
• DongLHChengSZhengZHistone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphomaJ Hematol Oncol201365323866964
   PubMed Web of Science ®Google Scholar
• KawadaJZouPMazitschekRBradnerJECohenJITubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosisJ Biol Chem200928425171021710919386607
   PubMed Web of Science ®Google Scholar
• BarbozaNMMedinaDJBudak-AlpdoganTPlitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximabCancer Biol Ther201213211412222336911
   PubMed Web of Science ®Google Scholar
• ShatzerANEspeyMGChavezMTuHLevineMChoenJIAscorbic acid kills Epstein-Barr virus (EBV) positive Burkitt lymphoma cells and EBV transformed B-cells in vitro, but not in vivoLeuk Lymphoma20135451069107823067008
   PubMed Web of Science ®Google Scholar
• LiZJYaoCLiuSFCytotoxic effect of icaritin and its mechanisms in inducing apoptosis in human Burkitt lymphoma cell lineBiomed Res Int2014201439151224895574
   PubMed Web of Science ®Google Scholar
• ShirleyCMChenJShamayMBortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphomaBlood2011117236297630321447826
   PubMed Web of Science ®Google Scholar
• SukFMLinSYLinRJBortezomib inhibits Burkitt’s lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expressionOncotarget2015628259882600126317903
   PubMedGoogle Scholar
• De VosSFlowersCWangDInterim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) non-Hodgkin’s lymphoma (NHL)J Clin Oncol201533Suppl 158535
   Web of Science ®Google Scholar
• BryanLJGordonLIBlocking tumor escape in hematologic malignancies: the anti-PD-1 strategyBlood Rev2015291253225260226
   PubMed Web of Science ®Google Scholar
• PosternakVColeMDStrategically targeting MYC in cancerF1000Res20165F1000
   Google Scholar
• AndersonMATsuiAWallMHuangDCRobertsAWCurrent challenges and novel treatment strategies in double hit lymphomasTher Adv Hematol201671526426834954
   PubMed Web of Science ®Google Scholar
• HartlMThe quest of targets executing MYC-dependent cell transformationFront Oncol2016613227313991
   PubMed Web of Science ®Google Scholar
• YunSVinceletteNDKnorrKL4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cellsBlood2016127222711272226917778
   PubMed Web of Science ®Google Scholar
• MuralidharanSVBhaduryJNilssonLMGreenLCMcLureKGNilssonJABET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cellsOncogene201635364689469726804177
   PubMed Web of Science ®Google Scholar
• DunleavyKAggressive B cell lymphoma: optimal therapy for MYC-positive double-hit, and triple-hit DLBCLCurr Treat Options Oncol201516125826634708
   PubMed Web of Science ®Google Scholar
• FrismantasVDobayMPRinaldiADrug response profiling to identify selective pharmacological activity in drug resistant ALLBlood20151262532
   Web of Science ®Google Scholar
• FischerUFosterMRinaldiAGenomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic optionNat Genet20154791020102926214592
   PubMed Web of Science ®Google Scholar
• McCombSAguade-GorgorioJHarderLActivation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALLSci Transl Med20168339339ra70
   Web of Science ®Google Scholar
• HanafordARArcherTCPriceADiSCoVERing innovative therapies for rare tumors: combining genetically accurate disease models with in silico analysis to identify novel therapeutic targetsClin Cancer Res201622153903391427012813
   PubMed Web of Science ®Google Scholar